5 Sep 2014 05:23
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
ABC.L Share News (ABC)
ABC Share
Price
ABC Share
News
ABC Share
Chat
ABC Share
Trades
ABC
Live RNS
ABC Share
Charts
ABC Broker
Ratings
ABC Directors
Deals
ABC Financial
Diary
ABC
Fundamentals
ABC Short
Positions
ABC
Media
ABC.L Information
- There is currently no data for ABC
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Abcam accquires Californian antibodies manufacturer
Mon, 28th Jan 2019 08:35
(Sharecast News) - Antibody supplier Abcam has acquired Californian monoclonal antibodies manufacturer Calico Biolabs for an undisclosed amount.Abcam said on Monday that the addition of Calico to the group would expand its already leading position in rabbit monoclonal antibodies - bringing a small catalogue of ready-made CAL antibodies for immunohistochemistry in addition to custom development services.While the AIM-listed firm did not disclose any financial terms of the deal, Abcam's board expects the transaction to "have a minimal impact on revenue and earnings".Abcam's John Baker said: "The acquisition of Calico represents execution of our strategy to provide the best and highest quality products to our diagnostic, biopharmaceutical and research customers.""By incorporating Calico's product portfolio and custom services, Abcam expands its offering of rabbit monoclonals for IHC, allowing development of more products for their most important targets, faster."As of 0835 GMT, Abcam shares had slipped 1.70% to 1,216p.
More News
4 Sep 2014 15:10
4 Sep 2014 05:23
3 Sep 2014 15:12
3 Sep 2014 05:19
2 Sep 2014 15:04
23 Jul 2014 09:01
Wednesday broker round-up UPDATE
Abcam: Canaccord Genuity ups target price from 375p to 400p and upgrades from hold to buy. ARM Holdings: Deutsche Bank cuts target price from 975p to 950p and maintains a hold recommendation. Credit Suisse lowers target price from 1125p to 1100p and leaves its outperform rating unaltered. Beazley:
Read more22 Jul 2014 09:37
Tuesday broker round-up UPDATE
Abcam: N+1 Singer places both its target price (prev.: 346p) and its sell recommendation under review. Amiad Water Systems: Oriel lowers target price from 350p to 340p and retains a buy recommendation. Ashmore Group: Espirito Santo ups target price from 371p to 404p, while downgrading to neutral.
Read more14 Jul 2014 10:11
Monday broker round-up UPDATE
Abcam: Numis cuts target price from 510p to 490p and stays with its add rating. ARM Holdings: Credit Suisse reduces target price from 1200p to 1125p and maintains an outperform rating. AstraZeneca: Jefferies reduces target price from 4850p to 4790p maintaining a hold recommendation. BP: Credit Su
Read more14 Jul 2014 09:11
30 Jun 2014 09:37
27 May 2014 09:31
DIRECTOR DEALINGS: Abcam Executives Awarded Shares
LONDON (Alliance News) - Abcam PLC Monday said Scientific Director Mark Bushfield and Commercial Director Philippe Cotrel were awarded matching shares at no cost under a share incentive plan.
Details are as follows.